You're Training Hard and Still Spraining Your Ankle. Here's Why.

COL5A1 encodes collagen type V, a key structural protein in tendons and ligaments. This isn’t the collagen in your skin. Type V collagen regulates the diameter and organization of type I collagen fibers, making it critical for ligament tensile strength. Without properly functioning COL5A1, your ligaments are geometrically weaker even if they have normal total collagen content.

The rs12722 T allele variant, present in roughly 30-35% of the population, is associated with significantly higher injury risk in repetitive-stress sports. People carrying the T allele show nearly double the rate of ligament and tendon injuries compared to those without it. The mechanism is simple: collagen fibers are organized less tightly, creating microstructural weakness that becomes apparent under mechanical stress.

You feel this as a ligament that’s quick to give way, even without obvious trauma. Your ankle turns inward on a slight incline. The sprain happens at intensities that wouldn’t injure most people. Physical therapy helps, but because the underlying collagen organization is weaker, you don’t fully return to the structural integrity of an unaffected person.

COL1A1 encodes collagen type I, the dominant structural protein in tendons and ligaments. Type I collagen provides tensile strength. When this gene works optimally, it produces collagen that can withstand significant mechanical stress without tearing. When variants reduce its expression or function, your connective tissue is simply weaker at the molecular level.

Common variants in COL1A1 reduce collagen expression by 10-30%, and roughly 25-30% of people carry one or more risk alleles. Even a 20% reduction in collagen production means your ligaments and tendons are mechanically weaker from day one, regardless of how much you train. The structural weakness is pre-existing, not acquired. You were born with ligaments that can’t tolerate the same stress loads as people with optimal COL1A1 variants.

You experience this as ankles that feel looser and less stable than your peers, even from childhood. Your ankle turns at odd angles. You’ve probably heard you have weak ankles. That’s not weakness from disuse or poor training. That’s your COL1A1 producing collagen at a lower rate than normal, making your ligaments structurally thin.

The VDR gene encodes the vitamin D receptor, a protein that sits on the surface of muscle and bone cells and allows them to respond to vitamin D. Without a functional VDR, your cells can’t use vitamin D even if your blood levels are normal. Vitamin D is not just for bone strength. It’s required for muscle protein synthesis after injury, for calcium signaling during muscle contraction, and for immune regulation during the inflammatory phase of healing.

Common VDR variants (BsmI, FokI polymorphisms), present in 30-50% of the population depending on ancestry, reduce the transcriptional activity of the vitamin D receptor. People with these variants require higher vitamin D levels to achieve the same biological response as people with optimal VDR variants. If your blood vitamin D level is 35 ng/mL and you have a VDR risk variant, your cells are getting the signal of someone with a level of 20 ng/mL.

After an ankle sprain, your muscles need to rebuild rapidly and your inflammation needs to be controlled. If your VDR is weak and your vitamin D is low-normal, both processes stall. You feel slower recovery, more stiffness, and less complete return of muscle function. When you return to training, you’re still functionally weakened from the previous injury.

SOD2 encodes superoxide dismutase 2, an enzyme that sits inside the mitochondria and converts superoxide, a reactive oxygen species, into hydrogen peroxide. This is the cell’s primary antioxidant defense. When an ankle ligament is damaged, there’s an immediate surge of reactive oxygen species. If your SOD2 is weak, oxidative stress overwhelms your cells. Damaged tissue breaks down faster than repair enzymes can rebuild it.

The Val16Ala variant, present in roughly 40% of people as the homozygous form, significantly impairs mitochondrial antioxidant capacity. People carrying this variant show higher markers of oxidative stress during and after exercise, slower muscle recovery, and greater susceptibility to DOMS (delayed onset muscle soreness). After an ankle sprain, the gap between damage and repair widens. Your tissues are being oxidized faster than they’re being rebuilt.

You notice this as persistent soreness and swelling that lasts longer than expected. Other people sprain their ankle, ice it for a few days, and are back to normal. You’re still swollen and sore two weeks later. Your inflammation isn’t resolving because oxidative stress is keeping immune cells activated. You’re also more prone to re-injury because the tissue hasn’t fully regained strength before you return to activity.

IL6 encodes interleukin-6, a cytokine that initiates the inflammatory response after tissue injury. Some inflammation is essential. It brings immune cells to clean up damaged tissue and signals repair mechanisms to activate. But IL6 is a double-edged sword. When IL6 signaling is too strong or too prolonged, inflammation becomes destructive. Immune cells stay activated too long and damage healthy tissue that’s trying to repair.

Common variants in the IL6 promoter region (rs1800795), present in roughly 30-40% of the population, increase IL6 production in response to injury. People with these variants mount a stronger inflammatory response to the same ankle sprain, which means greater tissue damage, more pain, and slower return to function. The inflammation you’re experiencing isn’t just healing. It’s becoming part of the problem.

You notice this as ankles that swell more than they should, bruise more than they should, and take longer to feel normal. After a sprain, your ankle puffs up like a balloon. The swelling persists even after icing and elevation. Other people have minimal swelling. That difference is partly your IL6 signaling running hotter than normal. Your body is fighting harder than it needs to, which paradoxically slows the transition from inflammation to repair.

TNF encodes tumor necrosis factor-alpha, a master inflammatory cytokine that amplifies the entire immune response. TNF is produced by immune cells in response to tissue damage. It signals for more immune cells to arrive, it increases pain sensitivity, and it promotes both repair and destructive inflammation depending on context. When TNF signaling is chronically elevated, tissue stays in an inflammatory state even during the healing phase.

Variants in the TNF promoter region (rs1800629, -308G/A), present in roughly 10-20% of people depending on ancestry, increase TNF production in response to injury. People carrying the A allele produce significantly more TNF after tissue damage and show prolonged elevation of TNF even weeks into recovery. This keeps inflammation switched on when it should be transitioning to repair.

You experience this as persistent baseline inflammation in your ankle. Even between sprains, your ankle feels slightly swollen, slightly stiff, slightly less stable than it should. Then you sprain it again, and the inflammation is far more intense than it should be for the severity of the injury. You’re stuck in a cycle where your ankle never fully returns to a normal, non-inflammatory baseline.